Context Therapeutics Inc. (6K9.F)

1.2400 -0.0300 (-2.36%) At close: 03:32PM CEST

Context Therapeutics Inc.

2001 Market Street
Suite 3915 Unit #15
Philadelphia, PA 19103
United States
267 225 7416
https://www.contexttherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 5

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Martin A. Lehr	Co-Founder, President, CEO & Director	679.79k	N/A	1984
Ms. Jennifer Minai-Azary	CFO & Treasurer	500.2k	N/A	1978
Mr. Alex C. Levit Esq.	Chief Legal Officer & Corporate Secretary	480k	N/A	1979
Mr. Christopher Beck M.B.A.	Senior Vice President of Operations	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Corporate Governance

Context Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.